Back to results
US 2015/0307551 A1Published application
Cytotoxic peptides and antibody drug conjugates thereof
AssigneePfizer Inc.
InventorsMatthew David DOROSKI, Andreas MADERNA, Christopher John O'DONNELL, Chakrapani SUBRAMANYAM, Beth VETELINO, Russell George DUSHIN, Pavel STROP, Edmund Idris GRAZIANI
Life of this patent
Estimating the term…
Abstract
The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.
Claims6
-66. (canceled)
A compound of formula IIIa:
- or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,
- R1 is hydrogen, C1-C8 alkyl or C1-C8 haloalkyl;
- R2 is hydrogen, C1-C8 alkyl or C1-C8 haloalkyl;
- R3A and R3B are either of the following:
- (i) R3A is C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 carbocyclyl, C1-C10 heterocyclyl, aryl, heteroaralkyl, aralkyl or halogen;
- and
- R3B is C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 carbocyclyl, C1-C10 heterocyclyl, aryl, heteroaralkyl, halogen or aralkyl;
- or
- (ii) R3A and R3B taken together are C2-C8 alkylene or C1-C8 heteroalkylene;
- R4A and R4B are either of the following:
- (i) R4A is hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 carbocyclyl, C1-C10 heterocyclyl, aryl, heteroaralkyl or aralkyl;
- and
- R4B is hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 carbocyclyl, C1-C10 heterocyclyl, aryl, heteroaralkyl or aralkyl;
- or
- (ii) R4A and R4B taken together are C2-C8 alkylene or C1-C8 heteroalkylene;
- R5 is
- optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C1-C8 alkyl, —O—(C1-C8 alkyl), —C(O)R′, —OC(O)R′, —C(O)OR′, —C(O)NH2, —C(O)NHR′, —C(O)N(R′)2, —NHC(O)R′, —S(O)2R′, —S(O)R′, —OH, halogen, —N3, —NH2, —NH(R′), —N(R′)2, —CN, —NHC(═NH)NH2, —NHCONH2, —S(═O)2R′ and —SR′, wherein each R′ is independently selected from the group consisting of hydrogen, C1-C8 alkyl and unsubstituted aryl;
- R11 is
- Y is —C2-C20 alkylene-, —C2-C20 heteroalkylene-, C3-C8 carbocyclo-, -arylene-, —C3-C8heterocyclo-, —C1-C10alkylene-arylene-, -arylene-C1-C10alkylene-, —C1-C10alkylene-(C3-C8carbocyclo)-, —(C3-C8carbocyclo)-C1-C10alkylene-, —C1-C10alkylene-(C3-C8heterocyclo)-, or —(C3-C8 heterocyclo)-C1-C10alkylene-;
- Z is
- R7 is independently selected for each occurrence from the group consisting of F, Cl, I, Br, NO2, CN and CF3;
- R10 is hydrogen, —C1-C10alkyl, —C3-C8carbocycle, aryl, —C1-C10heteroalkyl, —C3-C8heterocyclo, —C1-C10alkylene-aryl, -arylene-C1-C10alkyl, —C1-C10alkylene-(C3-C8carbocyclo), —(C3-C8 carbocyclo)-C1-C10alkyl, —C1-C10alkylene-(C3-C8heterocyclo), and -(C3-C8 heterocyclo)-C1-C10alkyl, where aryl on R10 comprising aryl is optionally substituted with [R7]h;
- h is 1, 2, 3, 4 or 5;
- and
- X is O or S;
- R6 is hydrogen, C1-C8 alkyl or C1-C8 haloalkyl;
- and
- h is 1, 2, 3, 4 or 5.
25 more elements
A compound of formula IIIb:
- or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,
- W is
- R1 is hydrogen, C1-C8 alkyl or C1-C8 haloalkyl;
- R2 is hydrogen, C1-C8 alkyl or C1-C8 haloalkyl;
- R3A and R3B are either of the following:
- (i) R3A is C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 carbocyclyl, C1-C10 heterocyclyl, aryl, heteroaralkyl, aralkyl or halogen;
- and
- R3B is C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 carbocyclyl, C1-C10 heterocyclyl, aryl, heteroaralkyl, halogen or aralkyl;
- or
- (ii) R3A and R3B taken together are C2-C8 alkylene or C1-C8 heteroalkylene;
- R4A and R4B are either of the following:
- (i) R4A is hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 carbocyclyl, C1-C10 heterocyclyl, aryl, heteroaralkyl or aralkyl;
- and
- R4B is hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 carbocyclyl, C1-C10 heterocyclyl, aryl, heteroaralkyl or aralkyl;
- or
- (ii) R4A and R4B taken together are C2-C8 alkylene or C1-C8 heteroalkylene;
- R5 is
- optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C1-C8 alkyl, —O—(C1-C8 alkyl), —C(O)R′, —OC(O)R′, —C(O)OR′, —C(O)NH2, —C(O)NHR′, —C(O)N(R′)2, —NHC(O)R′, —S(O)2R′, —S(O)R′, —OH, halogen, —N3, —NH2, —NH(R′), —N(R′)2, —CN, —NHC(═NH)NH2, —NHCONH2, —S(═O)2R′ and —SR′, wherein each R′ is independently selected from the group consisting of hydrogen, C1-C8 alkyl and unsubstituted aryl;
- R11 is
- Y is —C2-C20 alkylene-, —C2-C20 heteroalkylene-, —C3-C8 carbocyclo-, -arylene-, —C3-C8heterocyclo-, —C1-C10alkylene-arylene-, -arylene-C1-C10alkylene-, —C1-C10alkylene-(C3-C8carbocyclo)-, —(C3-C8carbocyclo)-C1-C10alkylene-, —C1-C10alkylene-(C3-C8heterocyclo)-, or -(C3-C8 heterocyclo)-C1-C10alkylene-;
- Z is
- L is an antibody;
- X is O or S.
20 more elements
A compound of formula IIIc:
- or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,
- W is
- R1 is hydrogen, C1-C8 alkyl or C1-C8 haloalkyl;
- R2 is hydrogen, C1-C8 alkyl or C1-C8 haloalkyl;
- R3A and R3B are either of the following:
- (i) R3A is C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 carbocyclyl, C1-C10 heterocyclyl, aryl, heteroaralkyl, aralkyl or halogen;
- and
- R3B is C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 carbocyclyl, C1-C10 heterocyclyl, aryl, heteroaralkyl, halogen or aralkyl;
- or
- (ii) R3A and R3B taken together are C2-C8 alkylene or C1-C8 heteroalkylene;
- R4A and R4B are either of the following:
- (i) R4A is hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 carbocyclyl, C1-C10 heterocyclyl, aryl, heteroaralkyl or aralkyl;
- and
- R4B is hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 carbocyclyl, C1-C10 heterocyclyl, aryl, heteroaralkyl or aralkyl;
- or
- (ii) R4A and R4B taken together are C2-C8 alkylene or C1-C8 heteroalkylene;
- R5 is
- optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C1-C8 alkyl, —O—(C1-C8 alkyl), —C(O)R′, —OC(O)R′, —C(O)OR′, —C(O)NH2, —C(O)NHR′, —C(O)N(R)2, —NHC(O)R′, —S(O)2R′, —S(O)R′, —OH, halogen, —N3, —NH2, —NH(R′), —N(R′)2, —CN, —NHC(═NH)NH2, —NHCONH2, —S(═O)2R′ and —SR′, wherein each R′ is independently selected from the group consisting of hydrogen, C1-C8 alkyl and unsubstituted aryl;
- R11′ is —Y—,
- Y is —C2-C20 alkylene-, —C2-C20 heteroalkylene-, —C3-C8 carbocyclo-, -arylene-, —C3-C8heterocyclo-, —C1-C10alkylene-arylene-, -arylene-C1-C10alkylene-, —C1-C10alkylene-(C3-C8carbocyclo)-, —(C3-C8carbocyclo)-C1-C10alkylene-, —C1-C10alkylene-(C3-C8heterocyclo)-, or —(C3-C8 heterocyclo)-C1-C10alkylene-;
- Z′ is
- L is an antibody;
- X is O or S.
20 more elements
A compound of formula IIId:
- or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,
- W is
- R1 is hydrogen, C1-C8 alkyl or C1-C8 haloalkyl;
- R2 is hydrogen, C1-C8 alkyl or C1-C8 haloalkyl;
- R3A and R3B are either of the following:
- (i) R3A is C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 carbocyclyl, C1-C10 heterocyclyl, aryl, heteroaralkyl, aralkyl or halogen;
- and
- R3B is C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 carbocyclyl, C1-C10 heterocyclyl, aryl, heteroaralkyl, halogen or aralkyl;
- or
- (ii) R3A and R3B taken together are C2-C8 alkylene or C1-C8 heteroalkylene;
- R4A and R4B are either of the following:
- (i) R4A is hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 carbocyclyl, C1-C10 heterocyclyl, aryl, heteroaralkyl or aralkyl;
- and
- R4B is hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 carbocyclyl, C1-C10 heterocyclyl, aryl, heteroaralkyl or aralkyl;
- or
- (ii) R4A and R4B taken together are C2-C8 alkylene or C1-C8 heteroalkylene;
- R5 is
- optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C1-C8 alkyl, —O—(C1-C8 alkyl), —C(O)R′, —OC(O)R′, —C(O)OR′, —C(O)NH2, —C(O)NHR′, —C(O)N(R)2, —NHC(O)R′, —S(O)2R′, —S(O)R′, —OH, halogen, —N3, —NH2, —NH(R′), —N(R′)2, —CN, —NHC(═NH)NH2, —NHCONH2, —S(═O)2R′ and —SR′, wherein each R′ is independently selected from the group consisting of hydrogen, C1-C8 alkyl and unsubstituted aryl;
- [linker] is a divalent linker;
- L is an antibody;
- X is O or S.
18 more elements
A compound of formula IIc:
- or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,
- R1′ is —Y—,
- Y is —C2-C20 alkylene-, —C2-C20 heteroalkylene-, —C3-C8 carbocyclo-, -arylene-, —C3-C8heterocyclo-, —C1-C10alkylene-arylene-, -arylene-C1-C10alkylene-, —C1-C10alkylene-(C3-C8carbocyclo)-, —(C3-C8carbocyclo)-C1-C10alkylene-, —C1-C10alkylene-(C3-C8heterocyclo)-, or -(C3-C8 heterocyclo)-C1-C10alkylene-;
- Z′ is
- L is an antibody;
- D is —C(R4A′)(R4B′)— or is absent;
- R2′ is hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, or is absent if , is present;
- R3A′ and R3B′ are either of the following:
- (i) R3A′ is C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 carbocyclyl, C1-C10 heterocyclyl, aryl, heteroaralkyl, aralkyl or halogen;
- and
- R3B′ is C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 carbocyclyl, C1-C10 heterocyclyl, aryl, heteroaralkyl, halogen or aralkyl, or R3B′ is C2-C4 alkylene and forms 5-7 member ring as indicated by ;
- or
- (ii) R3A′ and R3B′ taken together are C2-C8 alkylene or C1-C8 heteroalkylene;
- R4A′ and R4B′ are either of the following:
- (i) R4A′ is hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 carbocyclyl, C1-C10 heterocyclyl, aryl, heteroaralkyl or aralkyl;
- and
- R4B′ is hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 carbocyclyl, C1-C10 heterocyclyl, aryl, heteroaralkyl or aralkyl;
- or
- (ii) R4A′ and R4B′ taken together are C2-C8 alkylene or C1-C8 heteroalkylene;
- R5 is
- C1-C10 heterocyclyl, C3-C8 carbocycly and C6-C14 aryl optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of —C1-C8 alkyl, —C1-C8 alkyl-N(R′)2, —C1-C8 alkyl-C(O)R′, —C1-C8 alkyl-C(O)OR′—O—(C1-C8 alkyl), —C(O)R′, —OC(O)R′, —C(O)OR′, —C(O)N(R′)2, —NHC(O)R′, —S(O)2R′, —S(O)R′, —OH, halogen, —N3, —N(R′)2, —CN, —NHC(═NH)NH2, —NHCONH2, —S(═O)2R′ and —SR′, wherein each R′ is independently selected from the group consisting of hydrogen, C1-C8 alkyl and unsubstituted aryl, or two R′ can, together with the nitrogen to which they are attached, form a C1-C10 heterocyclyl;
- or R5 is
- optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C1-C8 alkyl, —C1-C8 alkyl-N(R′)2, —C1-C8 alkyl-C(O)R′, —C1-C8 alkyl-C(O)OR′, —O—(C1-C8 alkyl), —C(O)R′, —OC(O)R′, —C(O)OR′, —C(O)N(R′)2, —NHC(O)R′, —S(O)2R′, —S(O)R′, —OH, halogen, —N3, —N(R′)2, —CN, —NHC(═NH)NH2, —NHCONFI2, —S(═O)2R′, —SR′ and arylene-R′, wherein each R′ is independently selected from the group consisting of hydrogen, C1-C8 alkyl, C1-C8heterocyclyl, C1-C10alkylene-C3-C8heterocyclyl and aryl, or two R′ can, together with the nitrogen to which they are attached, form a C1-C10 heterocyclyl;
- R6 is hydrogen, —C1-C8 alkyl, —C2-C8 alkenyl, —C2-C8 alkynyl or —C1-C8 haloalkyl;
- R12 is hydrogen, C1-C4 alkyl, C1-C10 heterocyclyl or C6-C14 aryl;
- R13 is C1-C10 heterocyclyl;
- and
- X is O or S;
- provided that when R3A is hydrogen X is S.
26 more elements
Dependencies are inferred from the claim text.